Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant in ESR1 Mutated Breast Cancer
NCT03202862Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in breast cancer, sponsored by Fudan University. Primary endpoint: Tumour assessment at 10 years. Status: unknown.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03202862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202862.